Standardized Definition of Progression Independent of Relapse Activity (Pira) in Relapsing-Remitting Multiple Sclerosis
| dc.contributor.author | Muller, Jannis | |
| dc.contributor.author | Sharmin, Sifat | |
| dc.contributor.author | Lorscheider, Johannes | |
| dc.contributor.author | Ozakbas, Serkan | |
| dc.contributor.author | Karabudak, Rana | |
| dc.contributor.author | Horakova, Dana | |
| dc.contributor.author | Kalincik, Tomas | |
| dc.date.accessioned | 2025-05-25T19:24:27Z | |
| dc.date.available | 2025-05-25T19:24:27Z | |
| dc.date.issued | 2025 | |
| dc.description | Lugaresi, Alessandra/0000-0003-2902-5589; Foschi, Matteo/0000-0002-0321-7155 | en_US |
| dc.description.abstract | Importance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main Outcome and Measure For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over >= 5 years). Results Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and Relevance Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies. | en_US |
| dc.description.sponsorship | Swiss Science Foundation [P500PM_214230, P5R5PM_225288]; National Health and Medical Research Council Investigator grants [2026836, 2033165]; MS Australia; Biogen; Novartis; Merck; Roche; Teva; Sanofi Genzyme | en_US |
| dc.description.sponsorship | The work was supported by grants from the Swiss Science Foundation (P500PM_214230 and P5R5PM_225288 to Dr Mueller) and by National Health and Medical Research Council Investigator grants (2026836 to Dr Kalincik and 2033165 to Dr Roos). Dr Roos is supported by a MS Australia postdoctora lfellowship grant. The MS Base Foundation is anot-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva,and Sanofi Genzyme | en_US |
| dc.identifier.doi | 10.1001/jamaneurol.2025.0495 | |
| dc.identifier.issn | 2168-6149 | |
| dc.identifier.issn | 2168-6157 | |
| dc.identifier.scopus | 2-s2.0-105002792941 | |
| dc.identifier.uri | https://doi.org/10.1001/jamaneurol.2025.0495 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/6191 | |
| dc.language.iso | en | en_US |
| dc.publisher | Amer Medical Assoc | en_US |
| dc.relation.ispartof | JAMA Neurology | |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Standardized Definition of Progression Independent of Relapse Activity (Pira) in Relapsing-Remitting Multiple Sclerosis | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Lugaresi, Alessandra/0000-0003-2902-5589 | |
| gdc.author.id | Foschi, Matteo/0000-0002-0321-7155 | |
| gdc.author.scopusid | 56900313000 | |
| gdc.author.scopusid | 55028512500 | |
| gdc.author.scopusid | 54397364000 | |
| gdc.author.scopusid | 6602895100 | |
| gdc.author.scopusid | 6602766721 | |
| gdc.author.scopusid | 55053678000 | |
| gdc.author.scopusid | 6602736963 | |
| gdc.author.wosid | Sá, Maria/Agt-9846-2022 | |
| gdc.author.wosid | Soysal, Aysun/Aax-7696-2021 | |
| gdc.author.wosid | Horakova, Dana/D-4649-2011 | |
| gdc.author.wosid | Shaygannejad, Vahid/N-3495-2018 | |
| gdc.author.wosid | Ozakbas, Serkan/V-6427-2019 | |
| gdc.author.wosid | Roos, Izanne/Abo-3767-2022 | |
| gdc.author.wosid | Lugaresi, Alessandra/C-7743-2012 | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C4 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Muller, Jannis; Sharmin, Sifat; Roos, Izanne; Kalincik, Tomas] Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia; [Muller, Jannis; Sharmin, Sifat; Roos, Izanne; Kalincik, Tomas] Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, Melbourne, Vic, Australia; [Muller, Jannis; Lorscheider, Johannes; Benkert, Pascal; Kuhle, Jens; Kappos, Ludwig] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland; [Muller, Jannis; Lorscheider, Johannes; Benkert, Pascal; Kuhle, Jens; Kappos, Ludwig] Univ Hosp Basel, MS Ctr, Neurol Clin & Policlin, Basel, Switzerland; [Muller, Jannis; Lorscheider, Johannes; Benkert, Pascal; Kuhle, Jens; Kappos, Ludwig] Univ Basel, Basel, Switzerland; [Ozakbas, Serkan] Izmir Univ Econ, Med Point Hosp, Izmir, Turkiye; [Ozakbas, Serkan] Multiple Sclerosis Res Assoc, Izmir, Turkiye; [Karabudak, Rana] Yeditepe Univ Hosp, Yeditepe Fac Med, Neurol Sci Dept, Neurol Neuroimmunol Unit, Istanbul, Turkiye; [Horakova, Dana] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Horakova, Dana] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Horakova, Dana] Gen Univ Hosp, Prague, Czech Republic; [Weinstock-Guttman, Bianca] Jacobs MS Ctr Treatment & Res, Dept Neurol, Buffalo, NY USA; [Shaygannejad, Vahid] Isfahan Univ Med Sci, Esfahan, Iran; [Etemadifar, Masoud] Dr Etemadifar MS Inst, Neurol, Esfahan, Iran; [Alroughani, Raed] Amiri Hosp, Dept Med, Div Neurol, Sharq, Kuwait; [Patti, Francesco] GF Ingrassia, Dept Med & Surg Sci & Adv Technol, Catania, Italy; [Patti, Francesco] AOU Policlin G Rodol San Marco, UOS Sclerosi Multipla, Catania, Italy; [Eichau, Sara] Hosp Univ Virgen Macarena, Dept Neurol, Seville 41004, Spain; [Prat, Alexandre] CHUM MS Ctr, Montreal, PQ, Canada; [Prat, Alexandre] Univ Montreal, Montreal, PQ, Canada; [Lugaresi, Alessandra] IRCCS Ist Sci Neurol Bologna, Bologna, Italy; [Lugaresi, Alessandra] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy; [Tomassini, Valentina] Univ G dAnnunzio, Inst Adv Biomed Technol ITAB, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Kermode, Allan G.] Univ Western Australia, Perron Inst Neurol & Translat Sci, Nedlands, WA, Australia; [Amato, Maria Pia] Univ Florence, Dept NEUROFARBA, Florence, Italy; [Amato, Maria Pia] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy; [Turkoglu, Recai] Haydarpasa Numune Training & Res Hosp, Dept Neurol, Istanbul, Turkiye; [Altintas, Ayse] Koc Univ, Sch Med, Dept Neurol, Istanbul, Turkiye; [Altintas, Ayse] Koc Univ, Koc Univ Res Ctr Translat Med KUTTAM, Istanbul, Turkiye; [Buzzard, Katherine] Box Hill Hosp, Dept Neurosci, Melbourne, Vic, Australia; [Buzzard, Katherine] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkiye; [van der Walt, Anneke; Butzkueven, Helmut] Alfred Hosp, Dept Neurol, Melbourne, Vic, Australia; [Blanco, Yolanda] Hosp Clin Barcelona, Ctr Neuroimmunol, Serv Neurol, Barcelona, Spain; [Gerlach, Oliver] Acad MS Ctr Zuyd, Zuyderland Med Ctr, Dept Neurol, Sittard Geleen, Netherlands; [Gerlach, Oliver] Maastricht Univ, Med Ctr, Sch Mental Hlth & Neurosci, Dept Neurol, Maastricht, Netherlands; [Khoury, Samia J.] Amer Univ, Beirut Med Ctr, Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon; [Barnett, Michael] Brain & Mind Ctr, Sydney, NSW, Australia; [John, Nevin] Monash Univ, Sch Clin Sci, Dept Med, Melbourne, Vic, Australia; [John, Nevin] Monash Hlth, Dept Neurol, Clayton, Australia; [Lechner-Scott, Jeannette] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia; [Foschi, Matteo] S Maria Croci Hosp Ravenna, MS Ctr, Dept Neurosci, Neurol Unit, Ravenna, Italy; [Surcinelli, Andrea] S Maria Delle Croci Hosp, Dept Diagnost Imaging, AUSL Romagna, Ravenna, Italy; [van Pesch, Vincent] UCLouvain, Dept Neurol, Clin Univ St Luc, Brussels, Belgium; [Prevost, Julie] CSSS St Jerome, St Jerome, PQ, Canada; [Sa, Maria Jose] Ctr Hosp Univ Sao Joao, Dept Neurol, Porto, Portugal; [Maimone, Davide] Azienda Osped Emergenza Cannizzaro, Ctr Sclerosi Multipla, UOC Neurol, Catania, Italy; [D'hooghe, Marie] Natl MS Centrum, Deptt Neurol, Melsbroek, Belgium; [Hughes, Stella] Royal Victoria Hosp, Belfast, North Ireland; [Hodgkinson, Suzanne] Univ New South Wales, Immune Tolerance Lab, Ingham Inst, Sydney, NSW, Australia; [Hodgkinson, Suzanne] Univ New South Wales, Dept Med, Sydney, NSW, Australia; [McGuigan, Chris] St Vincents Univ Hosp, Dublin, Ireland; [Cartechini, Elisabetta] P O Unico Macerata, Neurol Unit, Ast Macerata, Macerata, Italy; [Taylor, Bruce] Royal Hobart Hosp, Hobart, Australia; [Spitaleri, Daniele] Azienda Osped Rilievo Nazl San Giuseppe Moscati Av, Avellino, Italy; [Slee, Mark] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [McCombe, Pamela] Univ Queensland, Dept Neurol, Brisbane, Qld, Australia; [Yamout, Bassem] Neurol Inst, Harley St Med Ctr, Abu Dhabi, U Arab Emirates | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.volume | 82 | |
| gdc.description.woscitationindex | Science Citation Index Expanded | |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W4409413459 | |
| gdc.identifier.pmid | 40227706 | |
| gdc.identifier.wos | WOS:001470351300001 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 13.0 | |
| gdc.oaire.influence | 3.5466297E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Male | |
| gdc.oaire.keywords | Adult | |
| gdc.oaire.keywords | Middle Aged | |
| gdc.oaire.keywords | sclerosi multipla, progressione | |
| gdc.oaire.keywords | Cohort Studies | |
| gdc.oaire.keywords | Disability Evaluation | |
| gdc.oaire.keywords | Multiple Sclerosis, Relapsing-Remitting | |
| gdc.oaire.keywords | Recurrence | |
| gdc.oaire.keywords | Disease Progression | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Female | |
| gdc.oaire.keywords | Human medicine | |
| gdc.oaire.keywords | Registries | |
| gdc.oaire.keywords | Retrospective Studies | |
| gdc.oaire.keywords | sclerosi multipla, progressione, biomarcatori | |
| gdc.oaire.popularity | 1.1946033E-8 | |
| gdc.oaire.publicfunded | true | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 33.7431 | |
| gdc.openalex.normalizedpercentile | 1.0 | |
| gdc.openalex.toppercent | TOP 1% | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.crossrefcites | 1 | |
| gdc.plumx.mendeley | 40 | |
| gdc.plumx.newscount | 2 | |
| gdc.plumx.pubmedcites | 1 | |
| gdc.scopus.citedcount | 11 | |
| gdc.virtual.author | Özakbaş, Serkan | |
| gdc.wos.citedcount | 14 | |
| relation.isAuthorOfPublication | 0750ade3-1d29-450d-8c26-aaa8708d1bb0 | |
| relation.isAuthorOfPublication.latestForDiscovery | 0750ade3-1d29-450d-8c26-aaa8708d1bb0 | |
| relation.isOrgUnitOfPublication | 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd | |
| relation.isOrgUnitOfPublication | fbc53f3e-d1d3-4168-afd8-e42cd20bddd9 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd |
